Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
Status:
Unknown status
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the efficacy and safety of pyrotinib combined with
albumin paclitaxel and trastuzumab in the treatment of Her2-positive early or locally
advanced breast cancer, and to explore RCB scores and TILs expression and other related
molecular markers for pyrrole the efficacy of the treatment with pyrotinib.